Radiation hotspots may boost lung cancer treatment — a trial puts it to the test

NCT ID NCT07718672

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial compares standard stereotactic ablative radiotherapy (SBRT) to a version that intentionally delivers higher radiation doses to the tumor (hotspots) in people with early-stage non-small cell lung cancer. The goal is to see if hotspots improve local tumor control without causing too many side effects. About 200 participants will be randomly assigned to one of the two approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stereotactic ablative radiotherapy (SBRT) with intentional radiation hotspots
What this could lead to
If successful, this approach could improve local tumor control for early-stage lung cancer patients without needing more invasive treatments.
What could go wrong
This is a phase 2 trial, so results are preliminary. The higher radiation dose may increase side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.